Diabetic Foot Ulcers Clinical Trial
Official title:
A Phase 3, Randomized, Double-blind, Parallel-group, Vehicle Controlled, Multicenter Study of the Efficacy and Safety of Granexin Gel in the Treatment of Diabetic Foot Ulcer (GAIT 1)
Verified date | May 2020 |
Source | FirstString Research, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether Granexin gel is safe and effective in the treatment of diabetic foot ulcers.
Status | Terminated |
Enrollment | 124 |
Est. completion date | May 27, 2020 |
Est. primary completion date | May 27, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Both male and female participants may participate in the study. To be eligible for entry into this study, a patient must meet all of the following Inclusion criteria: 1. Age 18 years or older 2. Established diagnosis of diabetes mellitus (type I or II) 3. Glycosylated hemoglobin (HbA1c) value < 12.0% at the screening visit 4. Diagnosis of neuropathic foot ulcer by 10g monofilament test, tuning fork (128 Hz), or cotton wisp 5. Designated foot ulcer meets the following criteria at both the screening and baseline visits: 1. Present for at least 4 weeks 2. Full-thickness cutaneous ulcer below the ankle surface 3. University of Texas grade A1 4. Wound area (after debridement) 1 to 40.0 cm2 5. Viable, granulating wound (investigator discretion) 6. Ankle brachial index = 0.7 at both the screening and baseline visits. If the ABI is >1.30, one of the following confirmatory tests must be performed for the patient to be considered eligible: 1. Does Not have a monophonic or biphasic flow (with the loss of reverse flow) in the artery of the foot with the target ulcer via doppler waveform analysis of the dorsalis pedis and posterior tibial arteries, as determined by standard practices of the investigator and the site. 2. Transcutaneous oxygen pressure (TcPO2) at the foot >40 mmHg Additionally, patients must meet all other protocol-defined eligibility criteria. 7. Signed informed consent 8. Female patients of childbearing potential must have a negative pregnancy test at screening and must agree to use hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence throughout until 2 weeks after the last administration of investigational product. Male patients must also agree to use contraception such as a condom. Exclusion Criteria: Patients will not be eligible for enrollment in the study if they meet any of the exclusion criterial listed below: 1. Change (decrease or increase) in size of the designated target ulcer by = 30% during the 7-day screening period 2. Cannot tolerate the off-loading methods or cannot comply with study related procedures 3. Has an ulcer that meets any of the following criteria: 1. Shows signs of severe clinical infection, defined as pus oozing from the ulcer site 2. Requires surgical debridement 3. Is positive for ß-hemolytic streptococci upon culture performed prior to screening debridement procedure 4. Has > 50% slough, significant necrotic tissue, bone, tendon, or capsule exposure 5. Is highly exuding (i.e., requires daily change of dressing) 4. Requires total contact cast 5. Ankle brachial pressure index < 0.7 6. Has a local or systemic infection or local lymphangitis = 0.5 cm 7. Has any 1 of the following (only 1 of the 2 tests is required): 1. A monophasic or biphasic flow (with loss of reverse flow) in the artery of the foot with the target ulcer via doppler waveform analysis of the dorsalis pedis and posterior tibial arteries 2. Transcutaneous oxygen pressure (TcPO2) at the foot <40 mgHg 8. Presence of active malignant or benign tumor of any kind, (with the exception to nonmelanoma skin cancer as per investigator's discretion) 9. Congestive heart failure (New York Heart Association class II-IV) 10. Coronary heart disease with ST segment elevation myocardial infarction or coronary artery bypass graft or percutaneous transluminal coronary angioplasty within the last 6 months 11. Active osteomyelitis of the foot with the target ulcer detected by x-ray, CT scan, or MRI 12. Active connective tissue disease 13. Acute or chronic Charcot's neuro-arthropathy as determined by clinical and/or radiographic examination 14. Active treatment with systemic corticosteroids or topical corticosteroids (for treatment of the target ulcer or any area of the foot). This does not include inhaled corticosteroids used for conditions other than treating the target ulcer or any area of the foot. Wash out period for systemic corticosteroids is 14 days for inclusion in this study. Wash out period for topical corticosteroids (for treatment of the target ulcer or any area of the foot) is 14 days for inclusion in the study) 15. Active treatment with systemic antibiotics (wash out period for systemic antibiotics is 7 days for the inclusion in the study) 16. Previous or current radiation therapy to the distal lower extremity or likelihood to receive this therapy during study participation 17. Pregnant or nursing mothers 18. Uncontrolled anemia (hemoglobin < 10 g/dL in females and < 12 g/dL in males) 19. Estimated glomerular filtration rate < 25 mL/min 20. Poor nutritional status, defined as an albumin < 25 g/L (< 2,500 mg/dl) 21. Significant peripheral edema as per investigator's discretion 22. Known inability or unavailability of a patient to complete required study visits during study participation 23. A psychiatric condition (e.g., suicidal ideation) or chronic alcohol or drug abuse problem, determined from the patient's medical history, which, in the opinion of the investigator, may pose a threat to patient compliance 24. Use of a platelet-derived growth factor within 28 days before screening 25. Use of any investigational drug or therapy within 28 days before screening 26. Has any other factor which may, in the opinion of the investigator, compromise participation and/or follow-up in the study |
Country | Name | City | State |
---|---|---|---|
Canada | Centre podiatrique et soins des plaies | Boucherville | Quebec |
Hungary | Clinexpert Kft. - Kaszasdulo utca 5. | Budapest | |
Hungary | Strazsahegy Medicina Bt., Zrinyi utca 226 | Budapest | |
India | Parul Sevashram Hospitals | Ahmedabad | Gujarat |
India | Shrey Hospital Pvt Ltd | Ahmedabad | Gujarat |
India | KLEs Dr. Prabakar Kore Hospital and Medical Research Center | Belgaum | |
India | Peoples College of Medical Science and Research Centre | Bhopal | |
India | Marwari Hospital and Research Centre | Guwahati | |
India | Surakshaka MultiSpecialty and Diabetes Hospital | Hyderabad | |
India | Convenient Hospitals Ltd., CHL - Hospitals | Indore | Madhya Pradesh |
India | KRM Hospital and Research Center | Lucknow | |
India | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Lucknow | |
India | Fortis Hospital | Mohali | |
India | K R Hospital and Research Institute | Mysore | |
India | Supe Heart and Diabetes Hospital and Research Centre | Nashik | |
India | Batra Hospital and Medical Research Center | New Delhi | |
India | Aman Hospital and Research Centre | Vadodara | |
India | Anand Multispecialty Hospital | Vadodara | Gujarat |
India | Anu Hospitals, Kovelamudivara Street | Vijayawada | |
Poland | Lubuskie Centrum Diabetologii UI. | Budziszynek | Zielon |
Poland | MIKOMED Sp. z o.o. ul. | Lódz . | Lódz .Plugowa |
Poland | Instytut Medycyny Wsi - oddz diabetologii ul. Jaczewskiego 2, 20-090 Lublin, Poland | Lublin | Jaczewskiego |
Poland | NZOZ MED ART. Poradnie Specjalistyczne Ks. Wladyslawa 27, 44-240 Zory, Poland | Zory | Wladyslawa 27 |
United States | Integral - Clinical Trials Solutions | Doral | Florida |
United States | Acclaim Bone & Joint | Fort Worth | Texas |
United States | Direct Helpers Research Center | Hialeah | Florida |
United States | New Hope Podiatry Group, Inc. | Los Angeles | California |
United States | Futuro Clinical Trials, LLC | McAllen | Texas |
United States | Nirvana Research Center | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
FirstString Research, Inc. |
United States, Canada, Hungary, India, Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of complete wound closure at Week 12 based on investigator assessment | Week 12 | ||
Secondary | Time in days to first complete wound closure of the target ulcer based on investigator assessment over the 12 week treatment period | Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02652754 -
Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers
|
Phase 1 | |
Completed |
NCT01070433 -
A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers
|
Phase 2 | |
Completed |
NCT00971048 -
Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds
|
N/A | |
Terminated |
NCT00762138 -
The AutoloGel™ Post-Market Surveillance (TAPS) Program
|
N/A | |
Completed |
NCT00578604 -
Non-Invasive Assessment of Wound Healing With Optical Methods
|
N/A | |
Completed |
NCT05417425 -
Omeza Products in Combination With Standard of Care for the Treatment of Diabetic Foot Ulcers
|
Phase 1 | |
Completed |
NCT02631512 -
Evaluation of Woulgan in Diabetic Foot Ulcer
|
Phase 4 | |
Terminated |
NCT01816633 -
Effectiveness of AutoloGel Therapy in Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT02222376 -
Effect of Topic Pirfenidone in Diabetic Ulcers
|
Phase 3 | |
Completed |
NCT01454401 -
LeucoPatch™ Study A Multicenter Study on the Effect of LeucoPatch™ in Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01221207 -
Instant Total Contact Cast to Heal Diabetic Foot Ulcers
|
N/A | |
Withdrawn |
NCT01105884 -
Clinical and Cost Effectiveness of Different Dressing Materials in Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01291160 -
Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers
|
Phase 2/Phase 3 | |
Completed |
NCT00536744 -
Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers
|
Phase 3 | |
Terminated |
NCT00316537 -
Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers
|
Phase 1/Phase 2 | |
Completed |
NCT00013299 -
Clinical Trials of Footwear in Patients With Diabetes-Study Arm 2,3
|
Phase 2 | |
Completed |
NCT00013286 -
A Prospective Study of Endothelial Dysfunction and Diabetic Foot Ulcer Risk
|
Phase 2 | |
Not yet recruiting |
NCT00916292 -
Safety Study of Topical Human FGF-1 for Wound Healing
|
Phase 1 | |
Completed |
NCT01154374 -
A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot)
|
Phase 2 | |
Not yet recruiting |
NCT02672280 -
Safety and Exploratory Efficacy Study of Collagen Membrane With Mesenchymal Stem Cells in the Treatment of Skin Defects
|
Phase 1/Phase 2 |